Infliximab biosimilar drug aliquots can be used for in vitro or in vivo experiments. Several other reference drugs are also available. The drug aliquots are generated by aliquoting (dividing and repackaging) the EU-licensed reference drug.
Find and order your therapeutic molecules through smart filters
Up to 10 batches of original drugs for examining batch-to-batch variations
Up to 80% less compared to the original pharmaceutical price
Shipment within days worldwide according to GDP-standards
Up to 80% less compared to the original pharmaceutical price
| Drug name | Flixabi® | |||
| INN | Infliximab biosimilar | |||
| API type | Infliximab is a chimeric human-murine IgG1 monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology. | |||
| Pharmacotherapeutic group | Immunosuppressants, tumour necrosis factor alpha (TNFα) inhibitors | |||
| ATC code | L04AB02 | |||
| Target of antibody | IgG1 | |||
| General function | Infliximab can be used to treat Rheumatoid arthritis, Paediatric and adult Crohn’s disease,Paediatric and adult Ulcerative colitis, Ankylosing spondylitis, Psoriatic arthritis and Psoriasis. | |||
| Short description | ||||
| Pharmacodynamic properties (Mechanism of action; Source EMA document) | Infliximab is a chimeric human-murine monoclonal antibody that binds with high affinity to both soluble and transmembrane forms of TNFα but not to lymphotoxin α (TNFß). | |||
| Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document) | Infliximab inhibits the functional activity of TNFα in a wide variety of in vitro bioassays. Infliximab prevented disease in transgenic mice that develop polyarthritis as a result of constitutive expression of human TNFα and when administered after disease onset, it allowed eroded joints to heal. In vivo, infliximab rapidly forms stable complexes with human TNFα, a process that parallels the loss of TNFα bioactivity. | |||
| Original license holder | ||||
| Marketing authorisation numbers | EU/1/16/1106/001-005 | |||
| Marketing authorisation holder | Samsung Bioepis NL B.V. Olof Palmestraat 10 2616 LR Delft The Netherlands | |||
| Name of the manufacturer of the biological active substance | FUJIFILM Diosynth Biotechnologies Denmark ApS Biotek Allé 1, Hillerød, 3400, Denmark Samsung BioLogics Co., Ltd. 300, Songdo bio-daero Yeonsu-gu, Incheon City, 21987, Korea, Republic of | |||
| Name and address of the manufacturer(s) responsible for batch release | Biogen Netherlands B.V. Prins Mauritslaan 13, 1171 LP, Badhoevedorp Netherlands Samsung Bioepis NL B.V. Olof Palmestraat 10 2616 LR Delft The Netherlands | |||
| Max shelf life | 48 months | |||
| Storage conditions | 2°C – 8°C | |||
| List of excipients | Sucrose Polysorbate 80 Monobasic sodium phosphate monohydrate (for pH-adjustment) Dibasic sodium phosphate heptahydrate (for pH-adjustment) |
Evidentic offers multiple batches of original drug aliquots in low binding Eppendorf tubes for research use only. We provide licence-free drug aliquots with long, short or even “negative shelf life” by storing the products at recommended temperatures (either 2-8°C or -80°C) and ensuring fully functional molecules for research purposes.
Evidentic GmbH
Am Mühlenberg 10
14476 Potsdam | Germany
